Serum Institute Expects WHO Emergency Approval For AstraZeneca Shot Soon

The Serum Institute CEO said a special purpose vehicle housing its pandemic-related products should be valued at $12 billion to $13 billion

Serum Institute CEO Adar Poonawalla.

The Serum Institute of India expects WHO emergency-use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine.

The chief executive said it is producing the vaccines for mid and low income countries.

Adar Poonawalla told the Reuters Next conference on Thursday that, “The emergency use licensure from the WHO (World Health Organization) should be available and coming through in the next week or two, hopefully, because we have submitted everything.”

The stockpiling of millions of doses of the Novavax coronavirus vaccine candidate would start from around April, said Poonawalla.

“It will be upwards of 40-50 million doses per month is what we are trying to stockpile of the Novavax product,” he said.

The Serum Institute CEO said a special purpose vehicle housing its pandemic-related products should be valued at $12 billion to $13 billion.

“We are in a unique position to be able to make so many different vaccines at a huge volume and capacity,” he said.

“For an investor to come in an at a $12-13 billion valuation, it will be a fantastic deal, leaving a lot of upside.”

Facebook Comments